Bausch + Lomb, a Valeant Pharmaceuticals company, remains the only firm with an FDA-approved accommodating IOL, the Crystalens AO. Andrew Chang, general manager and senior vice president of Bausch + Lomb US Surgical, highlighted clinical data from a study of long-term quality of vision and patient satisfaction with accommodating and multifocal IOLs conducted by John Hovanesian, MD. In this study of 117 patients, nearly three times as many Crystalens patients as multifocal IOL patients (44% vs. 16%) reported complete absence of glare and halos. This suggests that the accommodating IOL delivers better overall quality of vision and results in fewer problems with night driving.
At OIS@ASCRS, B+L announced a collaboration with IBM to develop an app for cataract surgeons that will be available on Apple’s iPhone and iPad and will have applications beyond just the premium channel. The app will help surgeons streamline their workflow and plan surgical interventions by delivering patient information and IOL options on a single, digital platform at the point of care. Patient information could include IOL calculations, corneal topography, historical surgical data, lifestyle preferences, and personalized IOL options. The app, which IBM will develop as part of its MobileFirst for iOS partnership with Apple, is expected to begin pilot testing later this year.
Andrew is the General Manager and Vice President of US Surgical for Bausch + Lomb, a subsidiary of Valeant International.